Features of prescription drug monitoring programs associated with reduced rates of prescription opioid-related poisonings

Drug and Alcohol Dependence

Volumn 184, Issue , 2018, Pages 26-32

  Pauly, N J ^a   Slavova, S ^b   Delcher, C ^c   Freeman, P R ^a   Talbert, J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Evaluation; Opioid; Poisoning; Policy; Prescription drug monitoring program

Indexed keywords

OPIATE; PRESCRIPTION DRUG; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG INTOXICATION; EMERGENCY WARD; FEMALE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT IDENTIFICATION; PRESCRIPTION DRUG MONITORING PROGRAM; PRESCRIPTION OPIOID RELATED POISONING; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; RISK FACTOR; STATISTICAL ANALYSIS; DRUG OVERDOSE; HOSPITAL EMERGENCY SERVICE; PRESCRIPTION DRUG MISUSE; TRENDS; UNITED STATES;

ADULT; ANALGESICS, OPIOID; DRUG OVERDOSE; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; PRESCRIPTION DRUG MISUSE; PRESCRIPTION DRUG MONITORING PROGRAMS; UNITED STATES;

EID: 85044348414     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2017.12.002     Document Type: Article

References (45)

1. Ashburn, M.A., The evolution of prescription drug monitoring programs. Pharmacoepidemiol. Drug Saf. 25 (2016), 852–853.
2. Bao, Y., Pan, Y., Taylor, A., Radakrishnan, S., Luo, F., Pincus, H.A., Schackman, B.R., Prescription drug monitoring programs are associated with sustained reductions in opioid prescribing by physicians. Health Aff. 35 (2016), 1045–1051.
3. Brady, J.E., Wunsch, H., DiMaggio, C., Lang, B.H., Giglio, J., Li, G., Prescription drug monitoring and dispensing of prescription opioids. Publ. Health Rep. 129 (2014), 139–147.
4. Centers for Disease Control and Prevention, Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. Morb. Mortal. Wkly. Rep. 60 (2011), 1487–1492.
5. Centers for Disease Control and Prevention, CDC Grand Rounds: Prescription Drug Overdoses—A U.S. Epidemic. 2012, Centers for Disease Control and Prevention, Atlanta, GA Morb. Mortal. Wkly. Rep.
6. Centers for Disease Control and Prevention, Prescription Drug Overdose Data and Statistics: Guide to ICD-9-CM and ICD-10 Codes Related to Poisoning and Pain. 2013, Centers for Disease Control and Prevention, Atlanta, GA.
7. Cicero, T.J., Ellis, M.S., Surratt, H.L., Kurtz, S.P., The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry 71 (2014), 821–826.
8. Curtis, L.H., Stoddard, J., Radeva, J.I., Hutchison, S., Dans, P.E., Wright, A., Woosley, R.L., Schulman, K.A., Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States. Health Serv. Res. 41 (2006), 837–855.
9. Davis, C.S., Pierce, M., Dasgupta, N., Evolution and convergence of state laws governing controlled substance prescription monitoring programs, 1998–2011. Am. J. Publ. Health 104 (2014), 1389–1395.
10. Delcher, C., Wagenaar, A.C., Goldberger, B.A., Cook, R.L., Maldonado-Molina, M.M., Abrupt decline in oxycodone-caused mortality after implementation of Florida's Prescription Drug Monitoring Program. Drug Alcohol Depend. 150 (2015), 63–68.
11. Dowell, D., Zhang, K., Noonan, R.K., Hockenberry, J.M., Mandatory provider review and pain clinic laws reduce the amounts of opioids prescribed and overdose death rates. Health Aff. 35 (2016), 1876–1883.
12. Dunning, T., Natural Experiments in the Social Sciences: A Design-Based Approach. 2012, Cambridge University Press.
13. Executive Office of the President, President Donald J. Trump is Taking Action on Drug Addiction and the Opioid Crisis. 2017, The White House, Washington, D.C.
14. FAIR Health, The Opioid Crisis Among the Privately Insured FAIR Health White Papers. 2016, FAIR Health, New York, NY.
15. Finley, E.P., Garcia, A., Rosen, K., McGeary, D., Pugh, M.J., Potter, J.S., Evaluating the impact of prescription drug monitoring program implementation: a scoping review. BMC Health Serv. Res., 17, 2017, 420.
16. Fitzmaurice, G., Laird, A., Ware, J., Applied Longitudinal Analysis. 2nd edition, 2011, Wiley.
17. Furlan, A.D., MacDougall, P., Pellerin, D., Shaw, K., Spitzig, D., Wilson, G., Wright, J., Overview of four prescription monitoring/review programs in Canada. Pain Res. Manage. 19 (2014), 102–106.
18. Green, T.C., Zaller, N., Rich, J., Bowman, S., Friedmann, P., Revisiting Paulozzi et al.’s “Prescription drug monitoring programs and death rates from drug overdose”. Pain Med. 12 (2011), 982–985.
19. Haffajee, R.L., Jena, A.B., Weiner, S.G., Mandatory use of prescription drug monitoring programs. JAMA 313 (2015), 891–892.
20. Healthcare Cost and Utilization Project, Hospital Inpatient Utilization Related to Opioid Overuse Among Adults, 1993–2012. Statistical Brief #177. 2014, Agency for Healthcare Research and Quality.
21. Healthcare Cost and Utilization Project, Clinical Classification Software (CCS) for ICD-9-CM. 2016 https://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp.
22. Islam, M.M., McRae, I.S., An inevitable wave of prescription drug monitoring programs in the context of prescription opioids: pros, cons and tensions. BMC Pharmacol. Toxicol., 15, 2014, 46.
23. McAllister, M.W., Aaronson, P., Spillane, J., Schreiber, M., Baroso, G., Kraemer, D., Smotherman, C., Gray-Eurom, K., Impact of prescription drug-monitoring program on controlled substance prescribing in the ED. Am. J. Emerg. Med. 33 (2015), 781–785.
24. Meara, E., Horwitz, J.R., Powell, W., McClelland, L., Zhou, W., O'Malley, A.J., Morden, N.E., State legal restrictions and prescription-opioid use among disabled adults. N. Engl. J. Med. 375 (2016), 44–53.
25. National Alliance for Model State Drug Laws, PDMP Dates of Operation. 2014 (Accessed on 11 February 2017) http://www.namsdl.org/library/580225E9-E469-AFA9-50E7579C1D738E71/.
26. National Alliance for Model State Drug Laws, Components of a Strong Prescription Monitoring Statute/program. 2015, National Alliance for Model State Drug Laws, Charlottesville, VA.
27. National Alliance for Model State Drug Laws, Prescription Drug Monitoring Programs. 2016 (Accessed on 11 February 2017) http://www.namsdl.org/prescription-monitoring-programs.cfm.
28. Naylor, B., Keith, T., Trump Says He Intends To Declare Opioid Crisis National Emergency. 2017, NPR.
29. Pardo, B., Do more robust prescription drug monitoring programs reduce prescription opioid overdose?. Addiction 112 (2017), 1773–1783.
30. Patrick, S.W., Fry, C.E., Jones, T.F., Buntin, M.B., Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Aff. 35 (2016), 1324–1332.
31. Paulozzi, L.J., Stier, D.D., Prescription drug laws, drug overdoses, and drug sales in New York and Pennsylvania. J. Publ. Health Policy 31 (2010), 422–432.
32. Paulozzi, L.J., Budnitz, D.S., Xi, Y., Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol. Drug Saf. 15 (2006), 618–627.
33. Paulozzi, L.J., Kilbourne, E.M., Desai, H.A., Prescription drug monitoring programs and death rates from drug overdose. Pain Med. 12 (2011), 747–754.
34. Prescription Drug Abuse Policy System, Prescription Drug Monitoring Program. 2016 (Accessed on 11 February 2017) http://pdaps.org/page/prescription-drug-monitoring-program/56d07899d6c9e7dd693689e1.
35. Reardon, J.M., Harmon, K.J., Schult, G.C., Staton, C.A., Waller, A.E., Use of diagnosis codes for detection of clinically significant opioid poisoning in the emergency department: a retrospective analysis of a surveillance case definition. BMC Emerg. Med., 16, 2016, 11.
36. Reifler, L.M., Droz, D., Bailey, J.E., Schnoll, S.H., Fant, R., Dart, R.C., Bucher Bartelson, B., Do prescription monitoring programs impact state trends in opioid abuse/misuse?. Pain Med. 13 (2012), 434–442.
37. Reisman, R.M., Shenoy, P.J., Atherly, A.J., Flowers, C.R., Prescription opioid usage and abuse relationships: an evaluation of state prescription drug monitoring program efficacy. Subst. Abuse 3 (2009), 41–51.
38. Rowe, C., Vittinghoff, E., Santos, G.M., Behar, E., Turner, C., Coffin, P.O., Performance measures of diagnostic codes for detecting opioid overdose in the emergency department. Acad. Emerg. Med. 24 (2017), 475–483.
39. Rudd, R., Seth, P., David, F., Scholl, L., Increases in Drug and Opioid-Involved Overdose Deaths—United States, 2010–2015. 2016, CDC, Atlanta, GA Morb. Mortal. Wkly. Rep.
40. Simeone, R., Holland, L., An Evaluation of Prescription Drug Monitoring Programs. 2006, Simeone Associates, Inc., Albany, NY.
41. Simoni-Wastila, L., Qian, J., Influence of prescription monitoring programs on analgesic utilization by an insured retiree population. Pharmacoepidemiol. Drug Saf. 21 (2012), 1261–1268.
42. Sohan, Murthy, America's Opioid Crisis, by the Numbers. 2017, Amino Group, San Francisco, CA https://amino.com/blog/opioid-epidemic-data-opioid-use-disorder.
43. Truven, Truven Health Analytics- MarketScan Databases. 2017.
44. Wastila, L.J., Bishop, C., The influence of multiple copy prescription programs on analgesic utilization. J. Pain Palliat. Care Pharmacother. 4 (1996), 3–19.
45. Weiss, A., Elixhauser, A., Barrett, M., Steiner, C., Bailey, M., O'Malley, L., Statistical Brief #219: Opioid-Related Inpatient Stays and Emergency Department Visits by State, 2009–2014. 2017, Agency for Healthcare Research and Quality, Rockville, MD.